Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Gastroenterology

How Often to Get an Endoscopy for Autoimmune Gastritis?

At a Glance

For autoimmune gastritis, international guidelines generally recommend an endoscopy every 3 years if you have severe stomach damage (high-risk), and every 5 years for mild damage. Your gastroenterologist will personalize this schedule based on your OLGA score, tumor risk, and other health factors.

The short answer is that your endoscopy schedule depends on the exact changes happening in your stomach lining. If your stomach shows advanced damage (high-risk), international guidelines generally recommend an endoscopy every 3 years [1][2]. If your damage is mild or confined to a small area (low-risk), you may only need an endoscopy every 5 years—or your doctor may recommend a personalized schedule based on your unique health profile [3][1].

Because autoimmune gastritis (AIG) increases the risk of developing two types of stomach tumors—gastric adenocarcinoma (stomach cancer) and Type 1 gastric neuroendocrine tumors (gNETs)—regular endoscopies are the best way to catch any changes early [4][3].

What the Major Guidelines Say

Gastroenterologists rely on major medical organizations to guide how often to perform endoscopies. The two most commonly referenced guidelines differ slightly in their approach:

  • The MAPS II Guidelines: These are the European guidelines for managing precancerous conditions in the stomach. MAPS II recommends that patients with severe, widespread atrophy (loss of normal stomach glands) have an endoscopy every 3 years [1][2]. For patients with mild damage, routine surveillance is not strictly required unless they have other risk factors, though many doctors still opt for a 3-to-5-year interval due to the risk of gNETs [1][3].
  • The AGA Guidelines: The American Gastroenterological Association acknowledges that the perfect, one-size-fits-all schedule for AIG is still unclear [3]. Instead of a strict timeline, the AGA recommends an individualized approach [3]. This means you and your doctor should decide on a schedule together (shared decision-making) based on your specific biopsy results and risk factors [3].

Understanding Your “OLGA” Stage

To determine whether you are high-risk or low-risk, pathologists use a scoring system called OLGA (Operative Link for Gastritis Assessment) [5]. Sometimes, a similar system called OLGIM is used. When you get an endoscopy, the doctor takes tiny tissue samples (biopsies) from different parts of your stomach [3][6]. The lab looks at these samples to see how much of your stomach lining shows a loss of normal stomach glands (atrophy) or has been replaced by altered cells (a process called intestinal metaplasia).

Note: In the United States, pathology labs do not always calculate your OLGA or OLGIM score automatically. You or your doctor may need to specifically request that your biopsies be scored using this system.

  • OLGA/OLGIM Stages III and IV (High-Risk): This means the atrophy or metaplasia is severe and widespread. Patients with these stages have a higher risk of gastric adenocarcinoma and need closer monitoring, typically every 3 years [5][7].
  • OLGA/OLGIM Stages I and II (Lower-Risk): This means the damage is mild or isolated. While the risk of adenocarcinoma is lower, patients with AIG can still develop gNETs, so surveillance remains important [8][9].

The Exception: Neuroendocrine Tumors (gNETs)

While the risk for traditional stomach cancer (adenocarcinoma) is the main driver for the 3-to-5-year guidelines, AIG also makes you prone to developing Type 1 gastric neuroendocrine tumors (gNETs) [4][10]. These tumors are usually small, slow-growing, and rarely spread [11][12].

If an endoscopy finds small gNETs, they can often be removed during the procedure itself [3][13]. However, because they tend to come back, your surveillance schedule will change. Guidelines recommend that if you have had a gNET removed, you should have follow-up endoscopies every 1 to 2 years, depending on how many tumors there were and their size [3].

Additional Risk Factors That May Shorten Your Timeline

Your doctor may recommend more frequent endoscopies (such as every 3 years instead of 5, or even sooner) if you have additional risk factors, including:

  • A past or current H. pylori infection: This common stomach bacteria dramatically increases the risk of stomach cancer when combined with AIG [14][1].
  • Family history: Having a first-degree relative with stomach cancer [1].
  • Age over 65 [15].
  • Pernicious anemia: Autoimmune gastritis destroys the cells that produce intrinsic factor, which is needed to absorb vitamin B12. When B12 deficiency becomes severe enough to cause pernicious anemia, it usually indicates that the AIG has progressed to a more advanced stage, placing you in a higher risk category [16][8].

What to Watch for Between Endoscopies

Because autoimmune gastritis behaves differently in everyone, your biopsy report is your roadmap. Even if you are on a comfortable 3-year or 5-year surveillance schedule, you should not wait for your next appointment if you develop new symptoms. Contact your doctor if you experience unexplained weight loss, persistent abdominal pain, dark or black stools, vomiting, or trouble swallowing, as these can warrant an earlier scope.

Common questions in this guide

How often do I need an endoscopy if I have autoimmune gastritis?
Most guidelines recommend an endoscopy every 3 years if you have severe stomach lining damage, or every 5 years for mild damage. However, the American Gastroenterological Association recommends a personalized schedule based on your specific biopsy results and risk factors.
What is an OLGA score on a stomach biopsy report?
The OLGA score is a system pathologists use to grade the severity of stomach lining damage from your biopsies. Stages III and IV indicate high-risk, widespread damage that usually requires closer monitoring with endoscopies every 3 years.
How does a neuroendocrine tumor (gNET) change my endoscopy schedule?
If a gastric neuroendocrine tumor (gNET) is found and removed during an endoscopy, you will need closer monitoring because these tumors can return. Guidelines typically recommend follow-up endoscopies every 1 to 2 years after removal.
Do H. pylori infections affect autoimmune gastritis?
Yes, having a past or current H. pylori infection dramatically increases your risk of developing stomach cancer when combined with autoimmune gastritis. Your doctor will likely recommend more frequent endoscopies if you have had this infection.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my latest endoscopy biopsies, what is my OLGA or OLGIM stage, and does it place me in a low-risk or high-risk category?
  2. 2.Did my biopsy show any signs of intestinal metaplasia, dysplasia, or neuroendocrine cell changes?
  3. 3.Have I been thoroughly tested for an H. pylori infection, and should we test for it again?
  4. 4.Considering both MAPS II and AGA guidelines, what specific endoscopy interval do you recommend for me, and why?
  5. 5.If you find a small neuroendocrine tumor during a future endoscopy, are you equipped to remove it during the same procedure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.

    Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al.

    Endoscopy 2019; (51(4)):365-388 doi:10.1055/a-0859-1883.

    PMID: 30841008
  2. 2

    Recent Guidelines on the Management of Patients with Gastric Atrophy: Common Points and Controversies.

    Matysiak-Budnik T, Camargo MC, Piazuelo MB, Leja M

    Digestive diseases and sciences 2020; (65(7)):1899-1903 doi:10.1007/s10620-020-06272-9.

    PMID: 32356261
  3. 3

    AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review.

    Shah SC, Piazuelo MB, Kuipers EJ, Li D

    Gastroenterology 2021; (161(4)):1325-1332.e7 doi:10.1053/j.gastro.2021.06.078.

    PMID: 34454714
  4. 4

    Autoimmune Atrophic Gastritis: A Clinical Review.

    Castellana C, Eusebi LH, Dajti E, et al.

    Cancers 2024; (16(7)) doi:10.3390/cancers16071310.

    PMID: 38610988
  5. 5

    Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients.

    Rugge M, Meggio A, Pravadelli C, et al.

    Gut 2019; (68(1)):11-17 doi:10.1136/gutjnl-2017-314600.

    PMID: 29306868
  6. 6

    Relationship between atrophic gastritis, serum ghrelin and body mass index.

    Panarese A, Romiti A, Iacovazzi PA, et al.

    European journal of gastroenterology & hepatology 2020; (32(10)):1335-1340 doi:10.1097/MEG.0000000000001868.

    PMID: 32773508
  7. 7

    OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients.

    Rugge M, Genta RM, Fassan M, et al.

    The American journal of gastroenterology 2018; (113(11)):1621-1628 doi:10.1038/s41395-018-0353-8.

    PMID: 30333540
  8. 8

    Incidence and Predictors of Gastric Neoplastic Lesions in Corpus-Restricted Atrophic Gastritis: A Single-Center Cohort Study.

    Dilaghi E, Dottori L, Pivetta G, et al.

    The American journal of gastroenterology 2023; (118(12)):2157-2165 doi:10.14309/ajg.0000000000002327.

    PMID: 37207305
  9. 9

    Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients.

    Rugge M, Bricca L, Guzzinati S, et al.

    Gut 2023; (72(1)):30-38 doi:10.1136/gutjnl-2022-327827.

    PMID: 35772926
  10. 10

    Occurrence and characteristics of endoscopic gastric polyps in patients with autoimmune gastritis (AGAPE study): A multicentric cross-sectional study.

    Massironi S, Gallo C, Lahner E, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025; (57(1)):198-205 doi:10.1016/j.dld.2024.07.024.

    PMID: 39112216
  11. 11

    Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.

    Wang X, Jiao J, Huh WJ, Zhang X

    Archives of pathology & laboratory medicine 2025; (150(1)):81-87 doi:10.5858/arpa.2025-0030-OA.

    PMID: 40509896
  12. 12

    Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.

    Chen YY, Guo WJ, Shi YF, et al.

    BMC gastroenterology 2023; (23(1)):440 doi:10.1186/s12876-023-03079-6.

    PMID: 38097952
  13. 13

    Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.

    Noh JH, Kim DH, Yoon H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(10)):2495-2502 doi:10.1007/s11605-021-04997-0.

    PMID: 33825119
  14. 14

    Autoimmune Gastritis in Korean Patients with Gastric Tumors: Clinicopathologic Correlations and Diagnostic Histological Features.

    Ahn S, Kim TS, Kushima R, et al.

    Gut and liver 2025; (19(2)):177-188 doi:10.5009/gnl240223.

    PMID: 39506312
  15. 15

    Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study.

    Lenti MV, Miceli E, Soykan I, et al.

    Gut 2026; doi:10.1136/gutjnl-2025-337458.

    PMID: 41791849
  16. 16

    Pernicious Anemia: The Hematological Presentation of a Multifaceted Disorder Caused by Cobalamin Deficiency.

    Esposito G, Dottori L, Pivetta G, et al.

    Nutrients 2022; (14(8)) doi:10.3390/nu14081672.

    PMID: 35458234

This page provides educational information on endoscopy guidelines for autoimmune gastritis. Always discuss your specific pathology results and screening schedule with your gastroenterologist.

Get notified when new evidence is published on autoimmune gastritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.